Impact of progestagen on activated protein C (APC) resistance among users of oral contraceptives

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 9, 2004, Pages 1594-1600

  Alhenc Gelas, M ^a   Plu Bureau, G ^b   Guillonneau, S ^b   Kirzin, J M ^c   Aiach, J M ^a   Ochat, N ^a   Scarabin, Pierre Yves ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

^c Centre d'Investigations Preventives et Cliniques   (France)

Author keywords

Activated protein C (APC) resistance; Coagulation; Oral contraceptive; Progestagen; Protein C; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 8; CHLORMADINONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; NOMEGESTROL ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; THROMBIN; PROGESTERONE DERIVATIVE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOEMBOLISM; THROMBOGENICITY; THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; ESTROGEN THERAPY; MIDDLE AGED; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PROGESTERONE CONGENERS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 13244277915     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00894.x     Document Type: Article

References (42)

1. Inman WHW, Vessey MP, Westerholm B, Engenlund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the committee on safety of drugs. Br Med J 1970; 2 203-9.
2. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 156: 1646-52.
3. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7.
4. World Health Organization Collaborative study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low œstrogen oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346 1582-8.
5. Jick H, Jick SS, Gurevwich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with different progestagen components. Lancet 1995; 346: 1589-93.
6. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-9.
7. Van Hylckama Vlieg A, Doggen CJM, Rosendaal FR. The thrombotic risk of different types of oral contraceptives and interaction with factor V Leiden and the prothrombin 20210A mutation: results of the MEGA study. J Thromb Haemost 2003; 1 (Suppl. 1): Abstract OC079.
8. Vasiliakis C, Jick H, Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610.
9. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
10. Winkler UH. Blood coagulation and oral contraceptives. Contraception 1998; 57: 203-9.
11. Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BN, Büller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
12. Middeldorp S, Meijers JCM, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Büller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
13. Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. Thromb Haemost 2000; 84: 9-14.
14. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism; pooled analysis of 8 case-control studies including 2 310 cases and 3 204 controls: Study Group for pooled-analysis in venous thromboembolism. Thromb Haemost 2001; 86: 809-16.
15. De Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
16. Tans G, van Hylckama Vlieg A, Thomassen MCLGD, Curvers J, Bertina R, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
17. Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C, Corrocher R. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
18. Meinardi JR, Henkens CMA, Heringa MP, van der Meer J. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coag Fibrinol 1997; 8: 152-4.
19. Rosing J, Tans G, Nicolaes GAF, Thomassen MCLGD, Van Oerle R, Van der Ploeg PMEN, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis. different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
20. Kluft C, de Maat MPM, Heinemann LAJ, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999; 354: 832-3.
21. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671-6.
22. Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-10.
23. Rosing J, Middeldorp S, Curvers J, Thomassen MCLGD, Nicolaes GAF, Meijers JCM, Bouma BN, Büller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
24. Gardiner C, Mackie IJ, Piegsa K, Furs SA, Guillebaud J, Machin S. Activated protein C resistance (APCR) and combined oral contraceptives. acquired APCR is more pronounced in women recieving desogestrel containing COCs than those containing levonorgestrel and is associated with low protein S levels. J Thromb Haemost 2003; 1 (Suppl. 1): Abstract P0883d.
25. Curvers J, Thomassen MCLGD, Nicolaes GAF, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
26. Niziel MR, van Oerle R, Thomassen MCLGD, Hamulyak K, Tans G, Rosing J. Acquired resistance to activated protein C in breast cancer patients. Thromb Haemost 1999; 82: Abstract 980: 311.
27. Hoibraaten E, Mowinckel MC, De Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C. results of a randomized, double-blind, placebo-controlled trial. Brit J Haematol 2001; 115: 415-20.
28. Niziel M, Van Oerle R, Thomassen MCLGD, Van Pampus ECM, Hamulyak K, Tans G, Rosing J. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003; 120: 117-22.
29. Curvers J, Thomassen MCLGD, Rimmer J, Hamulyak K, Van der Meer J, Tans G, Rosing J. Effects of hereditary and acquired risk factors for venous thrombosis on a thrombin-generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
30. Post M, Thomassen MCLGD, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CDA. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized placebo-controlled study in post menopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-21.
31. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin Blood 1999; 94: 3839-46.
32. Tripodi A, Chantarangkul V, Mannucci PM. Hyperprothrombinemia may result in acquired activated protein C resistance. Blood 2000; 96: 3295-6.
33. Legnani C, Cosmi B, Valdre L, Boggian O, Bernardi F, Coccheri S, Palareti G. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003; 1: 112-7.
34. Henkens CM, Bom VJ, Van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-9.
35. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinol 1995; 6 (Suppl. 1): 7-13.
36. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-92.
37. Kemmeren JM, Algra A, Meijers JCM, Bouma BN, Grobbee DE. Effect of second- and third-generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 2002; 87: 199-205.
38. Plu-Bureau G, Amiral J, Guize L, Scarabin PY. Safety of combined oral contraceptive pills. Lancet 1996; 347: 549.
39. Mink IB, Courey NG, Moore RH, Ambrus CM, Ambrus JL. Progestational agents and blood coagulation. IV. Changes induced by progestogen alone. Am J Obstet Gynecol 1972; 113: 739-43.
40. Basdevant A, Pelissier C, Conard J, Degrelle H, Guyene T, Thomas JL. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991; 44: 599-605.
41. Conard J, Basdevant A, Thomas JL, Ochsenbein E, Denis C, Guyene TT, Degrelle H. Cardiovascular risk factors and combined estrogen-progestin replacement therapy. a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995; 64: 957-61.
42. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of second and third generation oral contraceptives on the protein C system in the absence or presence of factor V Leiden mutation: a randomized trial. Blood 2004; 103 927-33.